Expert Opinion on Drug Safety, Volume 19, Issue 10 (2020)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Drug Safety, Volume 19, Issue 10 (2020)

See all volumes and issues
Vol 23, 2024 Vol 22, 2023 Vol 21, 2022 Vol 20, 2021 Volume 19, 2020 Vol 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Vol 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002
Download citations Download PDFs Download issue

Editorial

Editorial
An update on hip fracture risk associated with anticoagulant therapy: warfarin versus direct oral anticoagulants
Toshihiro Sugiyama
Pages: 1219-1220
Published online: 29 Sep 2020
CitationforAn update on hip fracture risk associated with anticoagulant therapy: warfarin versus direct oral anticoagulants | Full Text | References | PDF (161.4 KB) | EPUB
  • 1434 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access

Drug safety evaluation

Article
Safety of pembrolizumab for resected stage III melanoma
F. Pham & S. Dalle
Pages: 1221-1227
Published online: 24 Aug 2020
AbstractforSafety of pembrolizumab for resected stage III melanoma | Full Text | References | PDF (262.3 KB) | EPUB
  • 340 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients
Alice Indini & Mario Mandalà
Pages: 1229-1236
Published online: 14 Sep 2020
AbstractforSafety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients | Full Text | References | PDF (370.6 KB) | EPUB
  • 263 Views
  • 3 CrossRef citations
  • 0Altmetric

Review

CGRP inhibitors for migraine prophylaxis: a safety review
Eduardo Rivera-Mancilla, Carlos M. Villalón & Antoinette MaassenVanDenBrink
Pages: 1237-1250
Published online: 21 Sep 2020
AbstractforCGRP inhibitors for migraine prophylaxis: a safety review | Full Text | References | PDF (3.1 MB) | EPUB
  • 9261 Views
  • 23 CrossRef citations
  • 0Altmetric
Open Access
Anticholinergic medications and risk of dementia in older adults: Where are we now?
Satabdi Chatterjee, Ashna Talwar & Rajender R. Aparasu
Pages: 1251-1267
Published online: 31 Aug 2020
AbstractforAnticholinergic medications and risk of dementia in older adults: Where are we now? | Full Text | References | PDF (417.9 KB) | EPUB
  • 533 Views
  • 7 CrossRef citations
  • 0Altmetric
Safety of systemic treatments for Behçet’s syndrome
Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini & Florenzo Iannone
Pages: 1269-1301
Published online: 15 Sep 2020
AbstractforSafety of systemic treatments for Behçet’s syndrome | Full Text | References | PDF (1.8 MB) | EPUB
  • 218 Views
  • 5 CrossRef citations
  • 0Altmetric
The cognitive safety of antimuscarinics in the treatment of overactive bladder
George Araklitis & Dudley Robinson
Pages: 1303-1313
Published online: 08 Sep 2020
AbstractforThe cognitive safety of antimuscarinics in the treatment of overactive bladder | Full Text | References | PDF (364.5 KB) | EPUB
  • 370 Views
  • 2 CrossRef citations
  • 0Altmetric
New and emerging cardiovascular and antihypertensive drugs
Steven G. Chrysant & George S. Chrysant
Pages: 1315-1327
Published online: 29 Sep 2020
AbstractforNew and emerging cardiovascular and antihypertensive drugs | Full Text | References | PDF (410.2 KB) | EPUB
  • 514 Views
  • 4 CrossRef citations
  • 0Altmetric

systematic review and meta-analysis

Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
Francesco Massari, Veronica Mollica, Alessandro Rizzo, Laura Cosmai, Mimma Rizzo & Camillo Porta
Pages: 1329-1338
Published online: 08 Sep 2020
AbstractforSafety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis | Full Text | References | PDF (3.1 MB) | EPUB | Supplemental
  • 860 Views
  • 59 CrossRef citations
  • 0Altmetric

Original research

Article
Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study
Franco Citterio, Mitchell Henry, Dean Y Kim, Myoung Soo Kim, Duck-Jong Han, Takashi Kenmochi, Eytan Mor, Giuseppe Tisone, Peter Bernhardt, Maria Pilar Hernandez Gutierrez & Yoshihiko Watarai
Pages: 1339-1348
Published online: 20 Jul 2020
AbstractforWound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study | Full Text | References | PDF (427.5 KB) | EPUB | Supplemental
  • 464 Views
  • 3 CrossRef citations
  • 0Altmetric

Original Research

Article
The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses
Hye Jung Park, Jung-Won Park, Sae Hoon Kim, So-Yun Choi, Hee-Kyoo Kim, Chang-Gyu Jung, Min-Suk Yang, Dong Yoon Kang, Min-Kyoung Cho, Hyouk-Soo Kwon, Hye-Ryun Kang, Yong Won Lee & Allergy Work Group of KAAACI
Pages: 1349-1356
Published online: 18 Aug 2020
AbstractforThe HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses | Full Text | References | PDF (682.3 KB) | EPUB
  • 259 Views
  • 18 CrossRef citations
  • 0Altmetric
Article
Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance
Inyoung Lee, Todd A. Lee, Stephanie Y. Crawford, Ryan D. Kilpatrick, Gregory S. Calip & Jeremy D. Jokinen
Pages: 1357-1366
Published online: 27 Jul 2020
AbstractforImpact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance | Full Text | References | PDF (2.1 MB) | EPUB | Supplemental
  • 202 Views
  • 3 CrossRef citations
  • 0Altmetric

Letter to the Editor

Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
Emanuel Raschi, Paolo Caraceni, Elisabetta Poluzzi & Fabrizio De Ponti
Pages: 1367-1369
Published online: 25 Aug 2020
First Page PreviewforBaricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? | Full Text | References | PDF (154.1 KB) | EPUB
  • 1348 Views
  • 9 CrossRef citations
  • 0Altmetric
Reply to letter to the editor: baricitinib and toxicity is a rare occurrence
Ling Peng, Justin Stebbing & Ying-Jie Wang
Pages: 1371-1372
Published online: 24 Aug 2020
CitationforReply to letter to the editor: baricitinib and toxicity is a rare occurrence | Full Text | References | PDF (117.5 KB) | EPUB
  • 355 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access

Explore articles

Explore the most recently published articles

Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database
Xiaochen Wan et al.
Article | Published online: 20 Jun 2024
Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic
Jean-Luc Cracowski et al.
Comment | Published online: 19 Jun 2024
The evolving role of disproportionality analysis in pharmacovigilance
Michele Fusaroli et al.
Review Article | Published online: 19 Jun 2024
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database
Yating Qian et al.
Article | Published online: 18 Jun 2024
View all latest articles